Edoxaban
- Generic Name
- Edoxaban
- Brand Names
- Lixiana, Savaysa, Roteas
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30ClN7O4S
- CAS Number
- 480449-70-5
- Unique Ingredient Identifier
- NDU3J18APO
- Background
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic em...
- Indication
Edoxaban is indicated for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the tr...
- Associated Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Stroke, Systemic Embolism
- Associated Therapies
- -
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon
- Conditions
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 64920
- Registration Number
- NCT03563937
- Locations
- 🇩🇪
Many Locations, Multiple Locations, Germany
A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation
- First Posted Date
- 2018-04-05
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Raffaele De Caterina
- Target Recruit Count
- 25
- Registration Number
- NCT03489395
- Locations
- 🇮🇹
AORN S.ANNA e S.SEBASTIANO, Caserta, Italy
🇮🇹Presidio Ospedaliero S. Maria delle Grazie, Pozzuoli, Napoli, Italy
🇮🇹Ospedale P. Monaldi, Napoli, Italy
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 1512
- Registration Number
- NCT03463317
- Locations
- 🇩🇪
Vivantes Klinik Am Urban, Kardiologie, Berlin, Germany
🇩🇪Charité Universitätsmedizin Berlin, CBF, Kardiologie, Berlin, Germany
🇩🇪Vivantes Klinikum Neukölln, Kardiologie, Berlin, Germany
Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Jong Sung Kim
- Target Recruit Count
- 68
- Registration Number
- NCT03433235
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 168
- Registration Number
- NCT03395639
- Locations
- 🇭🇷
University Hospital Center Zagreb, Zagreb, Croatia
🇨🇦CHU Sainte-Justine, Montréal, Quebec, Canada
🇨🇦McMaster Children's Hospital, Hamilton, Ontario, Canada
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Portola Pharmaceuticals
- Target Recruit Count
- 108
- Registration Number
- NCT03310021
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
Variability of Whole Blood Clotting Time Measurements in Ex Vivo Human Blood Samples Spiked With Anticoagulants
- Conditions
- Interventions
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2020-05-20
- Target Recruit Count
- 12
- Registration Number
- NCT03296982
Medical Need of OAC Reversal
- Conditions
- Interventions
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53969
- Registration Number
- NCT03254147
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan
Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2022-08-18
- Target Recruit Count
- 234
- Registration Number
- NCT03247582
- Locations
- 🇭🇰
Prince of Wales Hospital (1083), Hong Kong, Hong Kong
🇭🇰Prince of Wales Hospital (1082), Hong Kong, Hong Kong
🇭🇰Queen Mary Hospital, Department of Neurology (1805), Hong Kong, Hong Kong
Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2022-05-06
- Target Recruit Count
- 300
- Registration Number
- NCT03247569
- Locations
- 🇹🇭
Bangkok Heart Hospital, Bangkok, Thailand
🇹🇭Bhumibol Adulyadej Hospital, Bangkok, Thailand
🇹🇭Thammasat University Hospital, Pathum Thani, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.